Literature DB >> 2168129

Management of hepatocellular carcinoma presenting as obstructive jaundice.

W Y Lau1, J W Leung, A K Li.   

Abstract

Eleven (3%) of 340 patients with hepatocellular carcinoma (HCC) presented with obstructive jaundice. The tumor extensively infiltrated the major bile ducts in eight patients. Jaundice was relieved by endoscopic endoprosthesis in four patients, nasobiliary drainage in two patients, percutaneous transhepatic stenting in one patient, and surgical intubation in one patient. The survival interval of these eight patients (mean +/- SD) was 35 +/- 20 days. Three patients had tumor fragments in the common bile ducts. In two patients, major hepatic resection was done after initial tube decomposition of the biliary system. One patient remained tumor-free on follow-up at 24 months, and the other patient had recurrent tumor detected on follow-up at 17 months after surgery. The tumor was irresectable in the third patient. Multiple surgical and endoscopic procedures kept the bile duct patent for 17 months before the patient died of the disease. Not all patients who present with obstructive jaundice due to HCC are terminally ill. With proper management, good palliation and occasional cure are possible.

Entities:  

Mesh:

Year:  1990        PMID: 2168129     DOI: 10.1016/s0002-9610(06)80023-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  22 in total

1.  Refractory pancreatitis secondary to ruptured hepatocellular carcinoma into the common bile duct.

Authors:  T S Yeh; Y Y Jan; T C Chao; R N Chien; T C Chen; M F Chen
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

3.  Refractory pancreatitis secondary to ruptured hepatocellular carcinoma into the common bile duct.

Authors:  T S Yeh; Y Y Jan; T C Chao; R N Chien; T C Chen; M F Chen
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

4.  Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation.

Authors:  N Sasahira; M Tada; H Yoshida; R Tateishi; S Shiina; K Hirano; H Isayama; N Toda; Y Komatsu; T Kawabe; M Omata
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 5.  Towards the optimization of management of hepatocellular carcinoma.

Authors:  Xi Feng; Madhava Pai; Malkhaz Mizandari; Tinatin Chikovani; Duncan Spalding; Long Jiao; Nagy Habib
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

6.  Change and significance of T-cell subsets and TNF-α in patients with advanced malignant obstructive jaundice treated by percutaneous transhepatic biliary external and internal drainage.

Authors:  Lidong Zhu; Xiaoping Chen
Journal:  Front Med China       Date:  2007-10-01

7.  Biliary tract invasion and obstruction by hepatocellular carcinoma: report of five cases.

Authors:  S T Lai; K T Lam; K C Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

8.  Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients.

Authors:  Lun-Xiu Qin; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Xin-Da Zhou; Hui-Chuan Sun; Qing-Hai Ye; Lu Wang; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 9.  Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.

Authors:  Tian Yang; Wan-Yee Lau; Han Zhang; Bin Huang; Jun-Hua Lu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

10.  Three cases of small hepatocellular carcinoma presenting as obstructive jaundice.

Authors:  N Ise; H Andoh; T Sato; O Yasui; T Kurokawa; H Kotanagi
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.